The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside- audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.09% lower. Veeva Systems is holding a Zacks Rank of #3 (Hold) right now. Shares of the provider of cloud-based software services for the life sciences industry have appreciated by 2.76% over the course of the past month, underpe ...

Wall Street analysts forecast that Veeva Systems (VEEV) will report quarterly earnings of $1.43 per share in its upcoming release, pointing to a year-over-year increase of 57.1%. It is anticipated that revenues will amount to $641.73 million, exhibiting an increase of 21.9% compared to the year-ago quarter. Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward t ...

With less than half of HCPs now accessible, coordinated engagement across sales, marketing, and medical makes the most of limited time PLEASANTON, Calif., May 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today unveiled the latest findings from its Veeva Pulse Field Trends Report. The analysis finds that healthcare professional (HCP) access has returned to its pre-pandemic state. Today, 45% of HCPs are accessible to biopharmas compared to 60% eighteen months ago, with half restricting engagement to th ...

Annual MedTech Breakthrough Awards program recognizes leading companies in medical devices and diagnostics PLEASANTON, Calif., May 22, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva MedTech was named "Best Overall MedTech Software" for the second year in a row in the 8th annual MedTech Breakthrough Awards program. The awards honor excellence and recognize innovation, commitment, and success across a range of health and medical technology categories. Veeva MedTech wins "Best Overa ...

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% sinc ...

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes BARCELONA, Spain, May 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will ...

Veeva Systems (VEEV) recently announced the availability of Vault Basics, a new offering that includes technology, training, and support designed for biotechs.Vault Basics enables rapidly expanding businesses to employ market-leading Veeva Vault applications, without any upfront or maintenance costs. Applications developed on industry best practices can be swiftly adopted by biotechs, providing a basis for scaling and growth management. Vault Basics is live at 10 biotechs to promote speed, compliance, and e ...

Delivers industry-leading Vault applications in a turnkey solution with no implementation costs for simple adoptionPLEASANTON, Calif., May 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva Vault Basics, a new offering that includes technology, training, and support designed for biotechs. Vault Basics equips fast-growing companies to deploy industry-leading Veeva Vault applications with zero implementation and maintenance costs. Biotechs can quickly adopt applicati ...

Veeva Systems Inc. (VEEV) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2024 performance and strategic deals, is expected to contribute further. Stiff competition and data security threats persist.Over the past six months, this current Zacks Rank #2 (Buy) stock has gained 28.6% compared with 12.6% growth of the industry and a 16.6% rise of the S&P 500 Composite.The renowned provider of cloud-based software appli ...

The latest trading session saw Veeva Systems (VEEV) ending at $203.86, denoting a +0.04% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. Meanwhile, the Dow lost 0.21%, and the Nasdaq, a tech-heavy index, added 0.29%.Heading into today, shares of the provider of cloud-based software services for the life sciences industry had lost 1.43% over the past month, lagging the Computer and Technology sector's gain of 1.39% and the S&P 500's gain of 1. ...